Skip to main content
. Author manuscript; available in PMC: 2015 Sep 21.
Published in final edited form as: Leukemia. 2011 Jul 15;25(12):1808–1814. doi: 10.1038/leu.2011.157

Table 5.

Characteristics of patients with a disease response of CR or CRp

Schedule
dose group		 Age
(years)		 Disease
status		 Cytogenetic risk
categorya 		Cytogenetics
at baseline		 Cytogenetics at response IWG
response		 Duration of
response
(months)
Weekly
    50 mg/m2 66 First relapse Intermediate 46,XY 46,XY CRp 2.4
    72 mg/m2 41 Refractory Unfavorable 47,XY, 9qht, t(11;19)(q23;p13.1),+21 Not done CRp 3.1
    72 mg/m2 40 Refractory Not done Not done Not done CR 1.7
    90 mg/m2 71 Primary refractory Unfavorable 46,XX, der(7)t;(5;7) (p13,p11.2) 46,XX CR (CRc) 9.1
Twice weekly
    40 mg/m2 73 Refractory Intermediate 46,XX 46,XX CR 19.2

Abbreviations: CR, complete response; CRc, cytogenetic complete response; CRp, complete response with incomplete recovery of platelets (<100 × 109/l); IWG, International Working Group.

a

Southwest Oncology Group classification.